Anna Vilgelm, MD, PhD

Selected Publications

Search in PubMed

• Vilgelm AE*, Saleh N, Riemenschneider K, Slesur L, Chen S, Johnson C, Yang J, Shattuck-Brandt R, Yan C, Johnson D, Al-Rohil R, Halilovic E, Kauffmann R, Kelley M, Ayers G, Richmond A. " MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21". Science Translational Medicine, August 2019. * - corresponding author
• Vilgelm AE, Richmond A. “Chemokines Modulate Immune Surveillance in Tumorigenesis, Metastasis and Response to Immunotherapy”. Frontiers in Immunology, February 2019.
• Yang J, Kumar A, Vilgelm AE, Chen SC, Ayers GD, Novitskiy SV, Joyce S, Richmond A. “Loss of CXCR4 in Myeloid Cells Enhances Antitumor Immunity and Reduces Melanoma Growth through NK Cell and FASL Mechanisms.” Cancer Immunol Res., August 14, 2018.
• Vilgelm AE*, Cobb P, Malikayil K, Flaherty D, Johnson CA, Raman D, Saleh N, Higgins B, Vara BA, Johnston JN, Johnsonh DB, Kelley MC, Chen SC, AyersGD, Richmond A. “MDM2 Antagonists Counteract Drug-Induced DNA Damage.” EBioMedicine, October 24, 2017. * - corresponding author
• Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, Ayers GD, Kelley MC, Sanders M, Mayer IA, Moses HL, Boothby M, Richmond A. “PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses.” Clin Cancer Res., Dec 21, 2016.
• Vilgelm, A. E.*, Johnson, D. B., Richmond, A. “Combinatorial approach to cancer immunotherapy: strength in numbers.” J Leukoc Biol., Jun 2, 2016. * - corresponding author
• Vilgelm, A. E. and Richmond, A. “Using avatars to win the fight over BRAF inhibitor resistance.” Pigment Cell Melanoma Res., May 17, 2016.
• Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM. “Melanoma-specific MHC-II expression represents a tumor-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy”. Nat Commun. Jan 29, 2016.
• Vilgelm, A. E.*, Johnson, C. A., Prasad, N., Yang, J., Chen, S. C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., Ecsedy, J. A., Shyr, Y., Levy, S. E., Richmond, A. “Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.” J Natl Cancer Inst., Dec 30, 2016. * - corresponding author
• Vilgelm A, Richmond A. “Combined therapies that induce senescence and stabilize p53 block melanoma growth and prompt antitumor immune responses.” Oncoimmunology, Mar 19, 2015.
• Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. “Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models”. Clin Cancer Res., Jul 7, 2015.
• Vilgelm AE, Pawlikowski JS, Liu Y, Hawkins OE, Davis TA, Smith J, Weller KP, Horton LW, McClain CM, Ayers GD, Turner DC, Essaka DC, Stewart SF, Sosman JA, Kelley MC, Ecsedy JA, Johnston JN and Richmond A. “Mdm2 and Aurora A inhibitors synergize to block melanoma growth by driving apoptosis and immune clearance of tumor cells”. Cancer Res., Jan 1 2015.
• Hockemeyer, K, Janetopoulous C, Terekhor A, Vilgelm AE, Hofmeister W, Wikswo J, Richmond A. “Engineered three-dimensional microfluidic device for interrogating cell-cell interactions in the tumor microenvironment.” Biomicrofluidics, Jul 15, 2014.
• Davis TA, Vilgelm AE, Richmond A, Johnston JN. “A Practical Preparation of (–)-Nutlin-3 at Gram-Scale” J Org Chem., Nov 1, 2013.
• Liu Y, Hawkins OE, Su Y, Vilgelm AE, Sobolik T, Thu YM, Kantrow S, Splittgerber RC, Short S, Amiri KI, Ecsedy JA, Sosman JA, Kelley MC, Richmond A. “Targeting Aurora Kinases Limits Tumor Growth through DNA Damage Mediated Senescence and Blockade of NF-κB Impairs Senescence.” EMBO Mol Med., Jan 5, 2013.
• Su Y, Vilgelm AE, Kelley MC, Hawkins OE, Liu Y, Boyd KL, Kantrow S, Splittgerber RC, Short SP, Sobolik T, Zaja-Milatovic S, Dahlman KB, Amiri KI, Jiang A, Lu P, Shyr Y, Stuart DD, Levy S, Sosman JA, Richmond A. “RAF265 inhibits the growth of advanced human melanoma tumors”. Clin Cancer Res., Apr 15, 2012.
• Vilgelm AE, Hong SM, Washington MK, Wei J, Chen H, El-Rifai W, Zaika A. “Characterization of ΔNp73 expression and regulation in gastric and esophageal tumors.” Oncogene., Oct 28, 2010.
• Vilgelm AE, Zaika AI, Prassolov VS. “The coordinated interaction of multifunctional members of the p53 family determines many key processes in multicellular organisms.” Mol Biol (Mosk). Jan-Feb 2011. Review.
• Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov VS, Zaika AI. “Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors.” Mol Cancer Ther., Mar 9, 2010.
• Vilgelm A, El-Rifai W, Zaika A. “Therapeutic prospects for p73 and p63: rising from the shadow of p53.” Drug Resist Updat., Aug-Oct 2008. Review.